Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives.
antiangiogenic therapy
immunoregulation
immunotherapy
tumor endothelial cells
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
05
2020
accepted:
21
07
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
The tumor microenvironment (TME) plays a central role in cancer development and progression. It represents a complex network of cancer cell (sub-)clones and a variety of stromal cell types. Recently, new technology platforms shed light on the cellular composition of the TME at very high resolution and identified a complex landscape of multi-lineage immune cells (e.g., T and B lymphocytes, myeloid cells, and dendritic cells), cancer associated fibroblasts (CAF) and tumor endothelial cells (TECs). A growing body of evidence suggests that metabolically, genetically and on their transcriptomic profile TECs exhibit unique phenotypic and functional characteristics when compared to normal endothelial cells (NECs). Furthermore, the functional role of TECs is multifaceted as they are not only relevant for promoting tumor angiogenesis but have also evolved as key mediators of immune regulation in the TME. Regulatory mechanisms are complex and profoundly impact peripheral immune cell trafficking into the tumor compartment by acting as major gatekeepers of cellular transmigration. Moreover, TECs are associated with T cell priming, activation and proliferation by acting as antigen-presenting cells themselves. TECs are also essential for the formation of tertiary lymphoid structures (TLS) within the tumor, which have recently been associated with treatment response to checkpoint antibody therapy. Further essential characteristics of TECs compared to NECs are their high proliferative potential as well as greatly altered gene expression profile (e.g., upregulation of pro-angiogenic, extracellular matrix remodeling, and stemness genes), which results in enhanced secretion of immunomodulatory cytokines and altered cell-surface receptors [e.g., major histocompatibility complex (MHC) and immune checkpoints]. The TEC phenotype may be rooted in an aggressive tumor micro-milieu based on cellular stress
Identifiants
pubmed: 32974337
doi: 10.3389/fcell.2020.00766
pmc: PMC7466447
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
766Informations de copyright
Copyright © 2020 Nagl, Horvath, Pircher and Wolf.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Trends Immunol. 2016 Mar;37(3):193-207
pubmed: 26839260
Eur J Cell Biol. 2001 Jan;80(1):99-110
pubmed: 11211940
Clin Cancer Res. 2001 Mar;7(3):524-32
pubmed: 11297243
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Crit Rev Oncog. 2016;21(3-4):155-168
pubmed: 27915969
Immunol Res. 2001;23(2-3):263-72
pubmed: 11444391
J Clin Invest. 1995 Jul;96(1):60-8
pubmed: 7542286
Science. 2000 Aug 18;289(5482):1197-202
pubmed: 10947988
Semin Cancer Biol. 2017 Jun;44:141-152
pubmed: 28315783
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
Mol Cancer. 2019 Jan 18;18(1):12
pubmed: 30657059
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
PLoS One. 2014 Mar 14;9(3):e91808
pubmed: 24632811
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Cancer Gene Ther. 2013 Jan;20(1):57-64
pubmed: 23175243
Cell Mol Immunol. 2016 May;13(3):347-53
pubmed: 27041636
Br J Cancer. 2014 Mar 4;110(5):1250-9
pubmed: 24496460
J Biol Chem. 2011 Oct 21;286(42):36808-19
pubmed: 21880716
Gastroenterol Res Pract. 2013;2013:210205
pubmed: 23606831
Methods Mol Biol. 2018;1845:99-118
pubmed: 30141010
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Blood. 2013 Jan 10;121(2):403-15
pubmed: 23074273
Science. 1997 Feb 14;275(5302):964-7
pubmed: 9020076
Nat Med. 2001 Feb;7(2):192-8
pubmed: 11175850
J Clin Invest. 2015 Sep;125(9):3365-76
pubmed: 26325033
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Cancer Res. 2004 Nov 15;64(22):8249-55
pubmed: 15548691
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):761-73
pubmed: 17166398
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Am J Pathol. 2014 Apr;184(4):1050-1061
pubmed: 24508126
Blood. 2009 Feb 26;113(9):1992-2002
pubmed: 19060246
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Oncoimmunology. 2020 Mar 9;9(1):1730538
pubmed: 32231867
Cancer Cell. 2011 Jan 18;19(1):125-37
pubmed: 21251616
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15975-80
pubmed: 17043243
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancer Res. 2012 Nov 1;72(21):5473-82
pubmed: 22962270
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Hepatology. 2009 Dec;50(6):1839-50
pubmed: 19824075
Am J Pathol. 2012 Mar;180(3):1294-1307
pubmed: 22245217
N Engl J Med. 2004 Jul 15;351(3):250-9
pubmed: 15254283
FASEB J. 2011 Jan;25(1):242-54
pubmed: 20876211
Nat Rev Immunol. 2014 Nov;14(11):719-30
pubmed: 25324123
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
PLoS One. 2018 Jul 31;13(7):e0200302
pubmed: 30063723
Nat Commun. 2020 Jan 27;11(1):538
pubmed: 31988323
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Am J Pathol. 2002 Mar;160(3):985-1000
pubmed: 11891196
BMC Cancer. 2015 Sep 22;15:643
pubmed: 26394830
Oncol Rep. 2017 Nov;38(5):2761-2773
pubmed: 29048623
Epigenetics. 2011 Aug;6(8):994-1000
pubmed: 21725204
Blood. 1996 Jul 15;88(2):667-73
pubmed: 8695814
PLoS One. 2015 Oct 28;10(10):e0141602
pubmed: 26509633
Oncotarget. 2017 Jan 17;8(3):5603-5618
pubmed: 27901498
Int J Biochem Cell Biol. 2009 Nov;41(11):2163-72
pubmed: 19782948
Oncotarget. 2017 Jul 11;8(28):45484-45495
pubmed: 28525375
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
Cancer Res. 2016 Jun 1;76(11):3200-10
pubmed: 27197162
Oncogene. 2008 Jun 12;27(26):3746-53
pubmed: 18223683
Immunity. 2007 May;26(5):643-54
pubmed: 17521585
J Immunol. 2007 Feb 1;178(3):1505-11
pubmed: 17237399
J Clin Oncol. 2009 Jul 1;27(19):3126-32
pubmed: 19451427
Am J Pathol. 2009 Dec;175(6):2657-67
pubmed: 19875502
Front Immunol. 2018 Dec 21;9:3081
pubmed: 30627131
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
J Exp Med. 2014 Apr 7;211(4):643-51
pubmed: 24663215
FASEB J. 2006 Apr;20(6):621-30
pubmed: 16581970
J Exp Med. 2010 Aug 30;207(9):1981-93
pubmed: 20713592
Blood. 2012 Feb 9;119(6):1345-52
pubmed: 22160377
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Cancer Res. 2013 Jan 1;73(1):86-96
pubmed: 23108139
Cells. 2019 Mar 21;8(3):
pubmed: 30901976
J Immunol. 2002 Jul 1;169(1):424-33
pubmed: 12077273
Clin Cancer Res. 2004 Nov 1;10(21):7171-8
pubmed: 15534089
Cell. 2014 Feb 13;156(4):744-58
pubmed: 24529377
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
J Cancer Res Clin Oncol. 2010 Nov;136(11):1737-43
pubmed: 20213100
Nature. 2010 Dec 9;468(7325):829-33
pubmed: 21102433
Nature. 2017 Apr 13;544(7649):250-254
pubmed: 28371798
FASEB J. 2015 Jan;29(1):227-38
pubmed: 25361735
Oncoimmunology. 2017 Jun 8;6(9):e1326442
pubmed: 28932632
Clin Cancer Res. 2014 Dec 15;20(24):6452-64
pubmed: 25320356
Front Immunol. 2018 Apr 05;9:527
pubmed: 29675018
J Clin Oncol. 2017 Dec 10;35(35):3916-3923
pubmed: 28902533
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a006429
pubmed: 22315715
Cell. 2012 Sep 28;151(1):56-67
pubmed: 23021215
Nat Rev Immunol. 2007 Oct;7(10):803-15
pubmed: 17893694
Cancer Res. 2010 Aug 1;70(15):6216-24
pubmed: 20647324
Int J Cancer. 1999 Jan 18;80(2):315-9
pubmed: 9935216
Cancer Immunol Immunother. 2015 Oct;64(10):1339-48
pubmed: 26267042
Cancer Cell. 2014 Mar 17;25(3):350-65
pubmed: 24651014
J Natl Cancer Inst. 2007 Aug 1;99(15):1188-99
pubmed: 17652277
Cell Death Differ. 2019 Mar;26(4):665-679
pubmed: 30692642
Cancer Res. 2011 Dec 1;71(23):7176-86
pubmed: 22037871
Cell Rep. 2012 Mar 29;1(3):191-9
pubmed: 22832193
Sci Rep. 2016 Jun 13;6:28039
pubmed: 27295191
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Am J Cancer Res. 2015 Jan 15;5(2):616-28
pubmed: 25973301
Nat Rev Clin Oncol. 2011 Mar 01;8(4):210-21
pubmed: 21364524
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Exp Cell Res. 2009 Jun 10;315(10):1715-23
pubmed: 19268462
Nat Rev Cancer. 2006 Jul;6(7):521-34
pubmed: 16794635
J Clin Invest. 2010 Nov;120(11):3953-68
pubmed: 20978347
Int J Mol Sci. 2017 Jun 30;18(7):
pubmed: 28665313
Nat Rev Cancer. 2010 Feb;10(2):138-46
pubmed: 20094048
Am J Pathol. 2000 Mar;156(3):899-909
pubmed: 10702407
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31600937
Cancer Cell. 2020 Jan 13;37(1):21-36.e13
pubmed: 31935371
Clin Cancer Res. 2010 Aug 1;16(15):3887-900
pubmed: 20554752
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Nat Cell Biol. 2018 Mar;20(3):243-251
pubmed: 29476153
Cell. 2013 Mar 28;153(1):139-52
pubmed: 23540695
Biochem Biophys Res Commun. 2010 Apr 16;394(4):947-54
pubmed: 20302845
J Cell Biol. 1994 Nov;127(4):1085-96
pubmed: 7525602
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Int J Mol Sci. 2018 Apr 18;19(4):
pubmed: 29670017
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5026-31
pubmed: 17360402
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
PLoS One. 2013 Nov 15;8(11):e80349
pubmed: 24260373
Cells. 2019 Jun 05;8(6):
pubmed: 31195728
Cancer Res. 2003 May 1;63(9):2322-9
pubmed: 12727857
Nat Med. 2008 Jan;14(1):28-36
pubmed: 18157142
Oncol Rep. 2009 Apr;21(4):933-9
pubmed: 19287991
Cytokine. 2014 Aug;68(2):94-100
pubmed: 24845798
Semin Immunol. 2018 Feb;35:35-47
pubmed: 29490888
Hepatology. 2015 May;61(5):1591-602
pubmed: 25529917
Front Immunol. 2016 Nov 09;7:491
pubmed: 27881983
Nat Immunol. 2004 Jan;5(1):74-80
pubmed: 14634646
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Cell Physiol Biochem. 2016;39(5):1665-1678
pubmed: 27639612
Neoplasia. 2015 Jan;17(1):66-78
pubmed: 25622900
Cell Metab. 2020 Apr 7;31(4):862-877.e14
pubmed: 32268117
Oncoimmunology. 2017 Dec 18;7(2):e1378844
pubmed: 29416939
Nat Rev Immunol. 2007 Sep;7(9):678-89
pubmed: 17717539
Cancer Cell. 2014 Aug 11;26(2):190-206
pubmed: 25117709
Front Oncol. 2018 Sep 10;8:367
pubmed: 30250827
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404865
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
J Immunol. 2007 Oct 1;179(7):4397-404
pubmed: 17878335
Cancer Res. 2014 Feb 1;74(3):665-74
pubmed: 24336068
Cancer Sci. 2017 Nov;108(11):2195-2203
pubmed: 28851003
Cancer Res. 2013 May 15;73(10):2943-8
pubmed: 23440426
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Cancer. 2007 Nov 15;110(10):2347-62
pubmed: 17849463
Immunol Today. 1995 Sep;16(9):449-57
pubmed: 7546210
Lancet. 2016 May 14;387(10032):2008-16
pubmed: 26969090
J Clin Invest. 2019 Jul 25;129(10):4350-4364
pubmed: 31343989
Cancer Cell. 2016 Dec 12;30(6):968-985
pubmed: 27866851
J Clin Immunol. 2013 May;33(4):826-37
pubmed: 23404187
Cancer Immunol Res. 2017 Nov;5(11):1005-1015
pubmed: 28947544
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Cancer Res. 2018 May 1;78(9):2370-2382
pubmed: 29449267
Cancer Cell. 2017 Mar 13;31(3):355-367
pubmed: 28238683
Cancer Res. 2011 Feb 1;71(3):976-87
pubmed: 21148069
Int J Cancer. 2002 Apr 20;98(6):946-51
pubmed: 11948478
Molecules. 2014 May 23;19(5):6851-62
pubmed: 24858271
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Cold Spring Harb Perspect Med. 2013 Jan 01;3(1):a006569
pubmed: 23085847
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Nat Rev Cancer. 2005 Jan;5(1):29-41
pubmed: 15630413
Cancer Immunol Res. 2014 Jul;2(7):632-42
pubmed: 24838938
PLoS One. 2014 Dec 01;9(12):e113910
pubmed: 25437864
J Biol Chem. 2002 Aug 2;277(31):27850-5
pubmed: 12023962
Cell Death Dis. 2018 Jan 25;9(2):115
pubmed: 29371595
Cancer Res. 2011 Sep 1;71(17):5678-87
pubmed: 21846823
Oncotarget. 2013 Sep;4(9):1472-83
pubmed: 23978847
Cell Immunol. 2018 Nov;333:34-45
pubmed: 29602445
Nat Commun. 2016 Apr 12;7:11302
pubmed: 27066737
J Cell Biol. 1988 Nov;107(5):1853-62
pubmed: 2460470
Oncogene. 2016 Oct 20;35(42):5489-5500
pubmed: 27065325
J Biol Chem. 2011 Aug 26;286(34):29913-21
pubmed: 21715322
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397